Next, variations in levels of serological markers and the urinary sCD163/creatinuria ratio were assessed at two time points in 93 LN patients (36 with LN-A and 57 with LN-IR) and variations in their SLEDAI-R used to consider therapeutic response/remission (negative delta SLEDAI-R), inactive/stable disease (unchanged delta), and SLE flare (positive delta) (Fig. 4D/F). The gene discussed is CD163; the disease is lobular neoplasia.